
Opinion|Videos|October 18, 2024
Defining Treatment Success with Oral Treatments in Patients with Plaque Psoriasis
Author(s)Eingun James Song, MD, FAAD
E. James Song, MD, FAAD, provides key takeaways on the treatment of patients with plaque psoriasis, highlighting ways to define treatment success and the effect of adverse events on long-term treatment choices.
Advertisement
Episodes in this series

Advertisement
Related to this article

For Healthy Skin Month, a dermatologist discusses winter sun protection, overlooked patients in skin cancer screening, bemotrizinol, and AI in detection.

For Healthy Skin Month, a dermatology nurse practitioner shares why sunscreen matters in winter and how clinicians can close gaps in skin cancer screening.

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.

Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin
2
Monitoring and Treatment Selection for Oral TYK2 Inhibitors in Psoriasis
3
CIndU Patient Demographics: Disease Duration, Diagnostic Delay, and Quality of Life
4
Bioelements and Celluma Collaborate on LED Facial Treatments
5


